Skip to main content
Premium Trial:

Request an Annual Quote

Envisagenics, Bristol Myers Squibb Partner to ID Cancer Therapy Alternative Splice Targets

NEW YORK – Envisagenics said on Tuesday it has entered into a research agreement with Bristol Myers Squibb (BMS) to identify alternative splicing-derived therapeutic targets with which to expand BMS's oncology pipeline.

The collaboration will leverage Envisagenics' cloud-based SpliceCore artificial intelligence platform to identify disease-specific splicing-derived targets using RNA-seq data from thousands of patients.

Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements. Other financial details were not disclosed.

SpliceCore consists of the proprietary SpliceTrap, SpliceDuo, and SpliceImpacts2 algorithms, which respectively detect alternative splicing (AS) profiles and significant AS variations; and prioritize biologically relevant AS events with therapeutic potential. 

The New York-based biotechnology company is also using SpliceCore in collaboration with Johnson & Johnson's Lung Cancer Initiative to analyze the initiative's data and build predictive models of lung cancer progression and risk.

Envisagenics also recently won a $2 million Small Business Innovation Research grant to develop its SpliceIO platform, which complements SpliceCore by seeking to identify splicing-derived neoantigens for cancer immunotherapies.

"Novel therapeutic targets are urgently needed for patients," Martin Akerman, Envisagenics' cofounder and chief technology officer, said in a statement, "and Envisagenics is thrilled to be collaborating with BMS as part of our quest for innovation."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.